Company news

Eton Pharmaceuticals, Inc. news in 2024

Eton Pharmaceuticals, Inc.'s news releases, calls and decks from 2024, newest first.

View company

Eton Pharmaceuticals Closes Acquisition of Increlex® (mecasermin injection)

December 19, 2024

Eton Pharmaceuticals Announces Final Readout of PKU GOLIKE® Clinical Trial

December 16, 2024

Eton Pharmaceuticals Appoints Ipek Erdogan-Trinkaus as Chief Commercial Officer

December 2, 2024

Eton Pharmaceuticals Announces Acquisition of U.S. Rights to Amglidia (Glyburide Oral Suspension)

November 24, 2024

Eton Pharmaceuticals Reports Third Quarter 2024 Financial Results

November 11, 2024

Eton Pharmaceuticals Awarded Second Patent for ET-400 (Hydrocortisone Oral Solution)

November 6, 2024

Eton Pharmaceuticals to Report Third Quarter 2024 Financial Results on Tuesday, November 12, 2024

November 5, 2024

SWK Holdings Provides Portfolio Update

October 16, 2024

Eton Pharmaceuticals, Inc to Acquire Increlex® (mecasermin injection) from Ipsen

October 2, 2024

Eton Pharmaceuticals to Participate at the H.C. Wainwright 26th Annual Global Investment Conference

August 21, 2024

Eton Pharmaceuticals Reports Second Quarter 2024 Financial Results

August 7, 2024

Eton Pharmaceuticals to Report Second Quarter 2024 Financial Results on Thursday, August 8, 2024

July 29, 2024

Eton Pharmaceuticals Announces FDA Acceptance of New Drug Application for ET-400 (Hydrocortisone Oral Solution)

July 14, 2024

Eton Pharmaceuticals Reports First Quarter 2024 Financial Results

May 8, 2024

Eton Pharmaceuticals to Present at the Citizens JMP Life Sciences Conference

April 30, 2024

Eton Pharmaceuticals Announces Submission to FDA of New Drug Application for ET-400 (Hydrocortisone Oral Solution)

April 29, 2024

Eton Pharmaceuticals to Report First Quarter 2024 Financial Results on Thursday, May 9, 2024

April 28, 2024

Eton Pharmaceuticals Announces Acquisition of PKU GOLIKE® for Phenylketonuria

March 21, 2024

Eton Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results

March 13, 2024

Eton Pharmaceuticals to Report Fourth Quarter and Full Year 2023 Financial Results on Thursday, March 14, 2024

February 28, 2024

Eton Pharmaceuticals Awarded U.S. Patent for Proprietary Hydrocortisone Oral Liquid Formulation

February 20, 2024

Eton Pharmaceuticals Announces Commercial Availability of Ultra-Rare Disease Product Nitisinone Capsules

February 1, 2024

Calls in 2024

Decks in 2024